In order to assess our compounds' pharmacokinetics, SwissADME, an online free tool, was used to evaluate the compounds' properties. It was found that lamellarins H/K (14/17) had only 1 Lipinski rule violation each, while lamellarin H ( ) also had one Veber's rule violation and one PAINS alert (Table ). Moreover, lamellarins S/Z (26/39) had one PAINS alert and one Veber's rule violation for lamellarin S . The four compounds had expected low GI absorption, and no blood-brain barrier penetration was predicted for any of them.